

# Omar Abdel-Rahman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4845553/publications.pdf>

Version: 2024-02-01

319  
papers

6,737  
citations

136740

32  
h-index

102304

66  
g-index

320  
all docs

320  
docs citations

320  
times ranked

11075  
citing authors

#	ARTICLE	IF	CITATIONS
1	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017. <i>JAMA Oncology</i> , 2019, 5, 1749.	3.4	1,691
2	Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study. <i>BMC Cancer</i> , 2018, 18, 688.	1.1	203
3	Prognostic value of site-specific metastases in pancreatic adenocarcinoma: A Surveillance Epidemiology and End Results database analysis. <i>World Journal of Gastroenterology</i> , 2017, 23, 1872.	1.4	133
4	Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 387-394.	1.1	128
5	Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis. <i>Future Oncology</i> , 2016, 12, 413-425.	1.1	115
6	Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. <i>Therapeutic Advances in Respiratory Disease</i> , 2016, 10, 183-193.	1.0	112
7	Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 101, 75-85.	2.0	105
8	Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. <i>Immunotherapy</i> , 2015, 7, 1213-1227.	1.0	77
9	Cigarette smoking as a risk factor for the development of and mortality from hepatocellular carcinoma: An updated systematic review of 81 epidemiological studies. <i>Journal of Evidence-Based Medicine</i> , 2017, 10, 245-254.	2.4	73
10	Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis. <i>Future Oncology</i> , 2015, 11, 2471-2484.	1.1	70
11	Validation of the 8th AJCC prognostic staging system for breast cancer in a population-based setting. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 269-275.	1.1	67
12	Combination Trans Arterial Chemoembolization (TACE) Plus Sorafenib for the Management of Unresectable Hepatocellular Carcinoma: A Systematic Review of the Literature. <i>Digestive Diseases and Sciences</i> , 2013, 58, 3389-3396.	1.1	65
13	Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 93, 127-135.	2.0	63
14	Expression, regulation and targeting of receptor tyrosine kinases in esophageal squamous cell carcinoma. <i>Molecular Cancer</i> , 2018, 17, 54.	7.9	62
15	Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: A systematic review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 91, 1-8.	2.0	55
16	Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: An updated systematic review and comparative meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 92, 194-207.	2.0	52
17	Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 75-83.	1.4	51
18	Gemcitabine-based chemotherapy for advanced biliary tract carcinomas. <i>The Cochrane Library</i> , 2018, 2018, CD011746.	1.5	51

#	ARTICLE	IF	CITATIONS
19	Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: Preclinical and clinical aspects. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 93, 18-27.	2.0	49
20	Treatment-related Death in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. <i>Clinical Oncology</i> , 2017, 29, 218-230.	0.6	49
21	Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1507-1518.	1.0	44
22	Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. <i>Medical Oncology</i> , 2013, 30, 655.	1.2	42
23	Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside. <i>Journal of the Egyptian National Cancer Institute</i> , 2013, 25, 165-171.	0.6	42
24	Prognostic value of site-specific extra-hepatic disease in hepatocellular carcinoma: a SEER database analysis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 695-701.	1.4	42
25	Global trends in mortality from malignant mesothelioma: Analysis of WHO mortality database (1994-2013). <i>Clinical Respiratory Journal</i> , 2018, 12, 2090-2100.	0.6	41
26	Incidence of Capillary Leak Syndrome as an Adverse Effect of Drugs in Cancer Patients: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2019, 8, 143.	1.0	40
27	A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors. <i>Immunotherapy</i> , 2016, 8, 665-674.	1.0	39
28	Evaluation of Circulatory RNA-Based Biomarker Panel in Hepatocellular Carcinoma. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 265-277.	1.6	37
29	Risk of cardiac death among cancer survivors in the United States: a SEER database analysis. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 873-878.	1.1	37
30	Assessment of the discriminating value of the 8th AJCC stage grouping for hepatocellular carcinoma. <i>Hpb</i> , 2018, 20, 41-48.	0.1	37
31	Impact of NCI Socioeconomic Index on the Outcomes of Nonmetastatic Breast Cancer Patients: Analysis of SEER Census Tract-Level Socioeconomic Database. <i>Clinical Breast Cancer</i> , 2019, 19, e717-e722.	1.1	37
32	Safety issues with the ALK inhibitors in the treatment of NSCLC: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 134, 56-64.	2.0	37
33	Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1063-1073.	1.1	36
34	Clinical correlates and prognostic value of different metastatic sites in metastatic renal cell carcinoma. <i>Future Oncology</i> , 2017, 13, 1967-1980.	1.1	36
35	Treatment-associated Fatigue in Cancer Patients Treated with Immune Checkpoint Inhibitors; a Systematic Review and Meta-analysis. <i>Clinical Oncology</i> , 2016, 28, e127-e138.	0.6	35
36	Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis. <i>Breast Cancer</i> , 2018, 25, 17-27.	1.3	34

#	ARTICLE	IF	CITATIONS
37	Changing epidemiology of elderly small cell lung cancer patients over the last 40 years; a <scp>SEER</scp> database analysis. <i>Clinical Respiratory Journal</i> , 2018, 12, 1093-1099.	0.6	33
38	5-Fluorouracil-related Cardiotoxicity; Findings From Five Randomized Studies of 5-Fluorouracil-based Regimens in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2019, 18, 58-63.	1.0	33
39	Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis. <i>Future Oncology</i> , 2014, 10, 1981-1992.	1.1	32
40	PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysis. <i>Immunotherapy</i> , 2016, 8, 1081-1089.	1.0	32
41	Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review. <i>Immunotherapy</i> , 2017, 9, 1175-1183.	1.0	32
42	Impact of baseline characteristics on outcomes of advanced HCC patients treated with sorafenib: a secondary analysis of a phase III study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 901-908.	1.2	32
43	Socioeconomic predictors of suicide risk among cancer patients in the United States: A population-based study. <i>Cancer Epidemiology</i> , 2019, 63, 101601.	0.8	32
44	Generalisability of Common Oncology Clinical Trial Eligibility Criteria in the Real World. <i>Clinical Oncology</i> , 2019, 31, e160-e166.	0.6	32
45	Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials. <i>Clinical Colorectal Cancer</i> , 2019, 18, 110-115.e2.	1.0	32
46	Outcomes of Surgery as Part of the Management of Metastatic Non-“Small-Cell Lung Cancer: A Surveillance, Epidemiology and End Results Database Analysis. <i>Cancer Investigation</i> , 2018, 36, 238-245.	0.6	31
47	Prognostic Value of Baseline ALBI Score Among Patients With Colorectal Liver Metastases: A Pooled Analysis of Two Randomized Trials. <i>Clinical Colorectal Cancer</i> , 2019, 18, e61-e68.	1.0	31
48	Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 295-305.	1.2	30
49	Association of long noncoding RNA and c-JUN expression in hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 869-877.	1.4	30
50	Immune checkpoints aberrations and gastric cancer; assessment of prognostic value and evaluation of therapeutic potentials. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 65-71.	2.0	30
51	Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 851-856.	1.1	30
52	Outcomes of non-metastatic colon cancer patients in relationship to socioeconomic status: an analysis of SEER census tract-level socioeconomic database. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1582-1587.	1.0	30
53	Risk of Selected Cardiovascular Toxicities in Patients With Cancer Treated With MEK Inhibitors: A Comparative Systematic Review and Meta-Analysis. <i>Journal of Global Oncology</i> , 2015, 1, 73-82.	0.5	29
54	Gastrointestinal adverse effects of cyclin-dependent kinase 4 and 6 inhibitors in breast cancer patients: a systematic review and meta-analysis. <i>Therapeutic Advances in Drug Safety</i> , 2017, 8, 337-347.	1.0	28

#	ARTICLE	IF	CITATIONS
55	Statin treatment and outcomes of metastatic pancreatic cancer: a pooled analysis of two phase III studies. <i>Clinical and Translational Oncology</i> , 2019, 21, 810-816.	1.2	28
56	Assessment of the prognostic and discriminating value of the novel bioscore system for breast cancer; a SEER database analysis. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 231-236.	1.1	25
57	Impact of timeliness of adjuvant chemotherapy and radiotherapy on the outcomes of breast cancer; a pooled analysis of three clinical trials. <i>Breast</i> , 2018, 38, 175-180.	0.9	25
58	Smoking and EGFR status may predict outcomes of advanced NSCLC treated with PD(L)1 inhibitors beyond first line: A meta-analysis. <i>Clinical Respiratory Journal</i> , 2018, 12, 1809-1819.	0.6	25
59	Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysis. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 129-141.	1.1	24
60	Epigenetic regulation of immune checkpoints: another target for cancer immunotherapy?. <i>Immunotherapy</i> , 2017, 9, 99-108.	1.0	24
61	Chronic Postoperative Opioid Use: A Systematic Review. <i>World Journal of Surgery</i> , 2019, 43, 2164-2174.	0.8	24
62	Clinical significance of serum <i>DRAM1</i> mRNA, <i>ARSA</i> mRNA, <i>hsa-miR-2053</i> and <i>lncRNA CRP1-86D1.3</i> axis expression in malignant pleural mesothelioma. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 3203-3211.	1.2	24
63	Prognostic impact of socioeconomic status among patients with malignant melanoma of the skin: a population-based study. <i>Journal of Dermatological Treatment</i> , 2020, 31, 571-575.	1.1	24
64	Causes of death in long-term lung cancer survivors: a SEER database analysis. <i>Current Medical Research and Opinion</i> , 2017, 33, 1343-1348.	0.9	23
65	Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations. <i>Endocrine-Related Cancer</i> , 2014, 21, R485-R493.	1.6	22
66	Immune-related neurological toxicities among solid tumor patients treated with immune checkpoint inhibitors: a systematic review. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 725-736.	1.4	22
67	Squamous Cell Carcinoma of the Bladder: A SEER Database Analysis. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e463-e468.	0.9	22
68	Clinical correlates and prognostic value of different metastatic sites in patients with malignant melanoma of the skin: a SEER database analysis. <i>Journal of Dermatological Treatment</i> , 2018, 29, 176-181.	1.1	22
69	RAF signaling in neuroendocrine neoplasms: From bench to bedside. <i>Cancer Treatment Reviews</i> , 2014, 40, 974-979.	3.4	21
70	Temozolomide-based combination for advanced neuroendocrine neoplasms: a systematic review of the literature. <i>Future Oncology</i> , 2015, 11, 1275-1290.	1.1	21
71	Doublet BRAF/MEK inhibition versus single-agent BRAF inhibition in the management of BRAF-mutant advanced melanoma, biological rationale and meta-analysis of published data. <i>Clinical and Translational Oncology</i> , 2016, 18, 848-858.	1.2	21
72	Does a patient's sex predict the efficacy of cancer immunotherapy?. <i>Lancet Oncology</i> , The, 2018, 19, 716-717.	5.1	21

#	ARTICLE	IF	CITATIONS
73	Hedgehog pathway aberrations and gastric cancer; evaluation of prognostic impact and exploration of therapeutic potentials. <i>Tumor Biology</i> , 2015, 36, 1367-1374.	0.8	20
74	Role of liver-directed local tumor therapy in the management of hepatocellular carcinoma with extrahepatic metastases: a SEER database analysis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 183-189.	1.4	20
75	Clinical evaluation of circulating miR-548a-3p and -20a expression in malignant pleural mesothelioma patients. <i>Biomarkers in Medicine</i> , 2018, 12, 129-139.	0.6	20
76	Impact of prior malignancies on outcome of colorectal cancer; revisiting clinical trial eligibility criteria. <i>BMC Cancer</i> , 2019, 19, 863.	1.1	20
77	Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 751-760.	1.1	19
78	Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations. <i>Tumor Biology</i> , 2014, 35, 10615-10625.	0.8	19
79	Management of Sacrococcygeal Chordoma. <i>Spine</i> , 2018, 43, E1157-E1169.	1.0	19
80	Impact of postmastectomy radiotherapy on the outcomes of breast cancer patients with T1â€²2 N1 disease. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 297-305.	1.0	19
81	Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials. <i>Clinical Colorectal Cancer</i> , 2019, 18, e385-e393.	1.0	19
82	Treatment choices and outcomes of non-metastatic hepatocellular carcinoma patients in relationship to neighborhood socioeconomic status: a population-based study. <i>International Journal of Clinical Oncology</i> , 2020, 25, 861-866.	1.0	19
83	Proteinuria in Patients with Solid Tumors Treated with Ramucirumab: A Systematic Review and Meta-Analysis. <i>Chemotherapy</i> , 2014, 60, 325-333.	0.8	18
84	Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience. <i>Journal of the Egyptian National Cancer Institute</i> , 2014, 26, 9-13.	0.6	18
85	Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis. <i>Future Oncology</i> , 2015, 11, 1109-1122.	1.1	18
86	Targeting mTOR pathway in gynecological malignancies: Biological rationale and systematic review of published data. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 108, 1-12.	2.0	18
87	Neurokinin-1 inhibitors in the prevention of nausea and vomiting from highly emetogenic chemotherapy: a network meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 396-406.	1.4	18
88	Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy. <i>Current Medical Research and Opinion</i> , 2018, 34, 903-910.	0.9	18
89	Exploring the differences between early-onset gastric cancer and traditional-onset gastric cancer. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 1157-1163.	0.6	18
90	Health-related quality of life in cancer patients treated with PD-(L)1 inhibitors: a systematic review. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1231-1239.	1.1	18

#	ARTICLE	IF	CITATIONS
91	Patient-related barriers to some virtual healthcare services among cancer patients in the USA: a population-based study. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 119-126.	0.6	18
92	Validation of the prognostic value of new sub-stages within the AJCC 8th edition of non-small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2017, 19, 1414-1420.	1.2	17
93	&lt;p&gt;&lt;em&gt;MET&lt;/em&gt; Inhibitors for the Treatment of Gastric Cancer: Whatâ€™s Their Potential?&lt;/p&gt;. <i>Journal of Experimental Pharmacology</i> , 2020, Volume 12, 349-361.	1.5	17
94	Evaluation of efficacy and safety of different pembrolizumab dose/schedules in treatment of non-small-cell lung cancer and melanoma: a systematic review. <i>Immunotherapy</i> , 2016, 8, 1383-1391.	1.0	16
95	Intraperitoneal chemotherapy and cytoreductive surgery for peritoneal metastases coupled with curative treatment of colorectal liver metastases: an updated systematic review. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 1-10.	1.4	16
96	Revisiting Oxaliplatin-based Regimens for Advanced Hepatocellular Carcinoma. <i>Current Oncology Reports</i> , 2014, 16, 394.	1.8	15
97	Use of angiotensin-converting enzyme inhibitors in the prophylaxis of anthracycline or trastuzumab-related cardiac dysfunction: preclinical and clinical considerations. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 829-837.	1.1	15
98	Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative systematic review and meta-analysis. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 847-858.	1.1	15
99	Risk of selected dermatological toxicities in cancer patients treated with <i>MEK</i> inhibitors: a comparative systematic review and meta-analysis. <i>Future Oncology</i> , 2015, 11, 3307-3319.	1.1	15
100	Risk of fatigue and hepatic and metabolic toxicities in patients with solid tumors treated with everolimus: a meta-analysis. <i>Future Oncology</i> , 2015, 11, 79-90.	1.1	15
101	Radical multimodality therapy for malignant pleural mesothelioma. <i>The Cochrane Library</i> , 2018, 2018, CD012605.	1.5	15
102	Sorafenib plus tegafur&ndash;uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study). <i>Journal of Hepatocellular Carcinoma</i> , 2018, Volume 5, 109-119.	1.8	15
103	A real-world, population-based study of the outcomes of patients with metastatic colorectal cancer to the peritoneum treated with or without cytoreductive surgery. <i>International Journal of Colorectal Disease</i> , 2020, 35, 719-725.	1.0	15
104	Assessment of the prognostic value of the 8th AJCC staging system for patients with clinically staged prostate cancer; A time to sub-classify stage IV?. <i>PLoS ONE</i> , 2017, 12, e0188450.	1.1	15
105	Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literature. <i>World Journal of Gastroenterology</i> , 2016, 22, 5896.	1.4	15
106	Everolimus-based combination for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): biological rationale and critical review of published data. <i>Tumor Biology</i> , 2015, 36, 467-478.	0.8	14
107	Risk of selected gastrointestinal toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1433-1445.	1.4	14
108	External beam radiotherapy for unresectable hepatocellular carcinoma. <i>The Cochrane Library</i> , 2017, 3, CD011314.	1.5	14

#	ARTICLE	IF	CITATIONS
109	Subsequent thoracic cancers among patients diagnosed with lung cancer: a SEER database analysis. <i>Current Medical Research and Opinion</i> , 2017, 33, 2009-2017.	0.9	14
110	Nonconventional patterns of benefit of solid tumors treated with PD-(L)1 inhibitors: a systematic review. <i>Immunotherapy</i> , 2017, 9, 995-1004.	1.0	14
111	Impact of age on toxicity and efficacy of 5-FU-based combination chemotherapy among patients with metastatic colorectal cancer; a pooled analysis of five randomized trials. <i>International Journal of Colorectal Disease</i> , 2019, 34, 1741-1747.	1.0	14
112	Pre-diagnostic body mass index trajectory in relationship to lung cancer incidence and mortality; findings from the PLCO trial. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 1029-1035.	1.0	14
113	Prostate Cancer Incidence and Mortality in Relationship to Family History of Prostate Cancer; Findings From The PLCO Trial. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e837-e844.	0.9	14
114	ECOG performance score 0 versus 1: impact on efficacy and safety of first-line 5-FU-based chemotherapy among patients with metastatic colorectal cancer included in five randomized trials. <i>International Journal of Colorectal Disease</i> , 2019, 34, 2143-2150.	1.0	14
115	Lung cancer incidence and mortality in relationship to hormone replacement therapy use among women participating in the PLCO trial: a post hoc analysis. <i>International Journal of Clinical Oncology</i> , 2020, 25, 885-891.	1.0	14
116	Depression and Suicidal Ideation Among Patients With Cancer in the United States: A Population-Based Study. <i>JCO Oncology Practice</i> , 2020, 16, e601-e609.	1.4	14
117	Risk of mucocutaneous toxicities in patients with solid tumors treated with everolimus; a systematic review and meta-analysis. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1529-1536.	1.1	13
118	Risk of selected gastrointestinal toxicities in patients with advanced non-small cell lung cancer receiving erlotinib: a systematic review and meta-analysis. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 465-475.	1.1	13
119	Insulin-like growth factor pathway aberrations and gastric cancer; evaluation of prognostic significance and assessment of therapeutic potentials. <i>Medical Oncology</i> , 2015, 32, 431.	1.2	13
120	Targeting the MEK signaling pathway in non-small cell lung cancer (NSCLC) patients with RAS aberrations. <i>Therapeutic Advances in Respiratory Disease</i> , 2016, 10, 265-274.	1.0	13
121	Early stage hepatocellular carcinoma in the elderly: A SEER database analysis. <i>Journal of Geriatric Oncology</i> , 2017, 8, 277-283.	0.5	13
122	Risk of Subsequent Primary Kidney Cancer After Another Malignancy: A Population-based Study. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e747-e754.	0.9	13
123	Challenging a dogma; AJCC 8th staging system is not sufficient to predict outcomes of patients with malignant pleural mesothelioma. <i>Lung Cancer</i> , 2017, 113, 128-133.	0.9	13
124	Validation of the Eighth AJCC New Substages for Bladder Cancer Among Different Staging Contexts. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e1095-e1106.	0.9	13
125	Surrogate end points for overall survival in trials of PD-(L)1 inhibitors for urinary cancers: a systematic review. <i>Immunotherapy</i> , 2018, 10, 139-148.	1.0	13
126	Validation of the AJCC 8th lung cancer staging system among patients with small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2018, 20, 550-556.	1.2	13



#	ARTICLE	IF	CITATIONS
127	A real-world, population-based study of patterns of referral, treatment, and outcomes for advanced pancreatic cancer. <i>Cancer Medicine</i> , 2018, 7, 6385-6392.	1.3	13
128	Pharmacological and clinical properties of lorlatinib in the treatment of <i>ALK</i> -rearranged advanced non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1547-1554.	0.9	13
129	Sex-Based Differences in Prognosis of Patients With Gastroenteropancreatic-Neuroendocrine Neoplasms. <i>Pancreas</i> , 2021, 50, 727-731.	0.5	13
130	Outcomes of metastatic colorectal cancer patients in relationship to prior and concurrent antibiotics use; individual patient data analysis of three clinical trials. <i>Clinical and Translational Oncology</i> , 2020, 22, 1651-1656.	1.2	13
131	Does the use of lapatinib increase the risk of fatigue and hepatic toxicities in patients with solid tumors? A critical literature review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 999-1008.	1.0	12
132	Efficacy and toxicity of sunitinib for non clear cell renal cell carcinoma (RCC): A systematic review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 238-250.	2.0	12
133	Risk of mucocutaneous toxicities in patients with solid tumors treated with lapatinib: a systematic review and meta-analysis. <i>Current Medical Research and Opinion</i> , 2015, 31, 975-986.	0.9	12
134	Risk of cardiovascular adverse events in patients with solid tumors treated with ramucirumab: A meta analysis and summary of other VEGF targeted agents. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 102, 89-100.	2.0	12
135	S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 5-20.	1.0	12
136	Comparison of three prognostic models for predicting cancer-specific survival among patients with gastrointestinal stromal tumors. <i>Future Oncology</i> , 2018, 14, 379-389.	1.1	12
137	Impact of prior malignancy on outcomes of stage IV esophageal carcinoma: SEER based study. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 417-423.	1.4	12
138	Re: Fabio Conforti, Laura Pala, Vincenzo Bagnardi, et al. Cancer Immunotherapy Efficacy and Patients' Sex: A Systematic Review and Meta-analysis. <i>Lancet Oncol</i> 2018;19:737-46. <i>European Urology</i> , 2018, 74, e139-e140.	0.9	12
139	Initial systemic chemotherapeutic and targeted therapy strategies for the treatment of colorectal cancer patients with liver metastases. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1767-1775.	0.9	12
140	Incidence and Mortality of Lung Cancer Among Never Smokers in Relationship to Secondhand Smoking: Findings From the PLCO Trial. <i>Clinical Lung Cancer</i> , 2020, 21, 415-420.e2.	1.1	12
141	Risk of pneumonitis with different immune checkpoint inhibitors in NSCLC. <i>Annals of Translational Medicine</i> , 2017, 5, 365-365.	0.7	12
142	Targeting vascular endothelial growth factor (VEGF) pathway in iodine-refractory differentiated thyroid carcinoma (DTC): From bench to bedside. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 45-54.	2.0	11
143	Systemic therapy options for advanced gastrointestinal stromal tumors beyond first-line imatinib: a systematic review. <i>Future Oncology</i> , 2015, 11, 1829-1843.	1.1	11
144	Second line systemic therapy options for advanced hepatocellular carcinoma; a systematic review. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 165-182.	1.1	11

#	ARTICLE	IF	CITATIONS
145	Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review. <i>Expert Review of Respiratory Medicine</i> , 2015, 9, 533-549.	1.0	11
146	Denosumab versus zoledronic acid to prevent aromatase inhibitors-associated fractures in postmenopausal early breast cancer; a mixed treatment meta-analysis. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 885-891.	1.1	11
147	Impact of tumor size on the outcome of patients with small renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 769-773.	1.1	11
148	Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib. <i>Clinical and Translational Oncology</i> , 2017, 19, 364-372.	1.2	11
149	Impact of smoking history on the outcomes of women with early-stage breast cancer: a secondary analysis of a randomized study. <i>Medical Oncology</i> , 2018, 35, 68.	1.2	11
150	Evaluation of the eighth American Joint Committee on Cancer staging system for malignant melanoma of the skin. <i>Future Oncology</i> , 2018, 14, 471-481.	1.1	11
151	Challenging a dogma: five-year survival does not equal cure in all colorectal cancer patients. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 187-192.	1.1	11
152	Validation of the 8th AJCC staging system for gastric cancer in a population-based setting. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 525-530.	1.4	11
153	Utilization of short-course radiation therapy for patients with nonmetastatic rectal adenocarcinoma in the United States. <i>Advances in Radiation Oncology</i> , 2018, 3, 611-620.	0.6	11
154	Outcomes of early-stage breast cancer patients treated with sequential anthracyclines and taxanes in relationship to relative dosing intensity: a secondary analysis of a randomized controlled trial. <i>Clinical and Translational Oncology</i> , 2019, 21, 239-245.	1.2	11
155	Toxicity patterns associated with chemotherapy/immune checkpoint inhibitor combinations: a meta-analysis. <i>Immunotherapy</i> , 2019, 11, 543-554.	1.0	11
156	Impact of diabetes comorbidity on the efficacy and safety of FOLFOX first-line chemotherapy among patients with metastatic colorectal cancer: a pooled analysis of two phase-III studies. <i>Clinical and Translational Oncology</i> , 2019, 21, 512-518.	1.2	11
157	Patterns and Trends of Cancer Screening in Canada: Results From a Contemporary National Survey. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 68-76.	2.3	11
158	Role of postoperative radiotherapy in the management of malignant pleural mesothelioma. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 276-284.	1.0	10
159	An analysis of clinical characteristics and patient outcomes in primary mediastinal sarcomas. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 1071-1076.	1.1	10
160	Validation of American Joint Committee on Cancer eighth staging system among prostate cancer patients treated with radical prostatectomy. <i>Therapeutic Advances in Urology</i> , 2018, 10, 35-42.	0.9	10
161	The Association Between the FTO rs9939609 Variant and Malignant Pleural Mesothelioma Risk: A Case-Control Study. <i>Genetic Testing and Molecular Biomarkers</i> , 2018, 22, 79-84.	0.3	10
162	Modified staging system for pulmonary carcinoids on the basis of lung cancer TNM system. <i>Clinical and Translational Oncology</i> , 2018, 20, 670-677.	1.2	10

#	ARTICLE	IF	CITATIONS
163	Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors. <i>Medical Oncology</i> , 2018, 35, 123.	1.2	10
164	Managing 5FU Cardiotoxicity in Colorectal Cancer Treatment. <i>Cancer Management and Research</i> , 2022, Volume 14, 273-285.	0.9	10
165	Cancer Burden Among Arab-World Females in 2020: Working Toward Improving Outcomes. <i>JCO Global Oncology</i> , 2022, 8, e2100415.	0.8	10
166	Evaluation of the 8th AJCC staging system for pathologically versus clinically staged pancreatic adenocarcinoma: A time to revisit a dogma?. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2018, 17, 64-69.	0.6	9
167	Revisiting Dukesâ€™ paradigm; some node positive colon cancer patients have better prognosis than some node negative patients. <i>Clinical and Translational Oncology</i> , 2018, 20, 794-800.	1.2	9
168	Efficacy and toxicity outcomes of elderly castrate-resistant prostate cancer patients treated with docetaxelâ€”A pooled analysis of 3 randomized studies. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 210-215.	0.8	9
169	A Realâ€”World, Populationâ€”Based Analysis of the Outcomes of Colorectal Cancer Patients with Isolated Synchronous Liver or Lung Metastases Treated with Metastasectomy. <i>World Journal of Surgery</i> , 2020, 44, 1604-1611.	0.8	9
170	Cannabis use among Canadian adults with cancer (2007â€”2016): results from a national survey. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 1025-1029.	0.7	9
171	Impact of socioeconomic status on presentation, treatment and outcomes of patients with pancreatic cancer. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 1233-1241.	0.6	9
172	Outcomes of Patients With Advanced Gastrointestinal Cancer in Relationship to Opioid Use: Findings From Eight Clinical Trials. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 575-581.	2.3	9
173	Risk of elevated transaminases in non-small cell lung cancer (NSCLC) patients treated with erlotinib, gefitinib and afatinib: a meta-analysis. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 223-234.	1.0	8
174	Treatment at a highâ€”volume centre is associated with improved survival among patients with nonâ€”metastatic hepatocellular carcinoma. <i>Liver International</i> , 2018, 38, 665-675.	1.9	8
175	Impact of baseline characteristics on extensiveâ€”stage SCLC patients treated with etoposide/carboplatin: A secondary analysis of a phase III study. <i>Clinical Respiratory Journal</i> , 2018, 12, 2519-2524.	0.6	8
176	Integrating Systemic Therapies into the Multimodality Treatment of Resectable Colorectal Liver Metastases. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-4.	0.7	8
177	Prediagnostic BMI and thyroid cancer incidence in the PLCO trial. <i>Future Oncology</i> , 2019, 15, 3451-3456.	1.1	8
178	Immune checkpoint inhibitors and non-small-cell lung cancer management: 2018 update. <i>Immunotherapy</i> , 2019, 11, 149-153.	1.0	8
179	Outcomes of metastatic breast cancer patients in relationship to diseaseâ€”free interval following primary treatment of localized disease; a pooled analysis of two clinical trials. <i>Breast Journal</i> , 2019, 25, 823-828.	0.4	8
180	Impact of Baseline Cardiovascular Comorbidity on Outcomes in Women With Breast Cancer: A Real-world, Population-based Study. <i>Clinical Breast Cancer</i> , 2019, 19, e297-e305.	1.1	8

#	ARTICLE	IF	CITATIONS
181	Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. The Cochrane Library, 2020, 1, CD011313.	1.5	8
182	Prognostic value of HPV status among patients with hypopharyngeal carcinoma: a population-based study. Clinical and Translational Oncology, 2020, 22, 1645-1650.	1.2	8
183	Risk of selected gastrointestinal toxicities in breast cancer patients treated with regimens containing lapatinib; a pooled analysis of randomized controlled studies. Expert Review of Anticancer Therapy, 2014, 14, 1229-1242.	1.1	7
184	Adjuvant systemic treatment for elderly breast cancer patients; addressing safety concerns. Expert Opinion on Drug Safety, 2014, 13, 1443-1467.	1.0	7
185	Irinotecan-based regimens for recurrent glioblastoma multiform: a systematic review. Expert Review of Neurotherapeutics, 2015, 15, 1255-1270.	1.4	7
186	Principles of a risk evaluation and mitigation strategy (REMS) for breast cancer patients receiving potentially cardiotoxic adjuvant treatments. Expert Opinion on Drug Safety, 2016, 15, 911-923.	1.0	7
187	Prostascor: A Simplified Tool for Predicting Outcomes among Patients with Treatment-naive Advanced Prostate Cancer. Clinical Oncology, 2017, 29, 732-738.	0.6	7
188	Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV). Drug Design, Development and Therapy, 2017, Volume11, 947-954.	2.0	7
189	Impact of Duration of Neoadjuvant Radiation on Rectal Cancer Survival: A Real World Multi-center Retrospective Cohort Study. Clinical Colorectal Cancer, 2018, 17, e21-e28.	1.0	7
190	The Expanding Role of Systemic Therapy in the Management of Hepatocellular Carcinoma. Canadian Journal of Gastroenterology and Hepatology, 2018, 2018, 1-4.	0.8	7
191	Impact of Prior Local Treatment on the Outcomes of Metastatic Hormone-Sensitive Prostate Cancer: Secondary Analysis of a Randomized Controlled Trial. Clinical Genitourinary Cancer, 2018, 16, 466-472.	0.9	7
192	Impact of Prior Malignancy on Survival Outcomes of Stage IV Pancreatic Adenocarcinoma: SEER-Based Cohort. Journal of Gastrointestinal Cancer, 2019, 50, 794-800.	0.6	7
193	Predictors of toxicity-related hospitalization in four randomized studies of 5-fluorouracil-based chemotherapy in metastatic colorectal cancer. International Journal of Colorectal Disease, 2019, 34, 675-680.	1.0	7
194	Prognostic impact of baseline quality of life status among patients with advanced gastric cancer; results from two randomized studies. Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 711-715.	0.7	7
195	Real-world patterns of chemotherapy administration and attrition among patients with metastatic colorectal cancer. International Journal of Colorectal Disease, 2021, 36, 493-499.	1.0	7
196	Influenza and pneumonia-attributed deaths among cancer patients in the United States; a population-based study. Expert Review of Respiratory Medicine, 2021, 15, 393-401.	1.0	7
197	Targeting the hepatocyte growth factor/mesenchymal epithelial transition pathway in gastric cancer: biological rationale and clinical applications. Expert Review of Anticancer Therapy, 2015, 15, 235-245.	1.1	6
198	Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with ramucirumab: a systematic review and meta-analysis. Expert Opinion on Drug Safety, 2015, 14, 1495-1506.	1.0	6

#	ARTICLE	IF	CITATIONS
199	Combined Chemohormonal Strategy in Hormone-Sensitive Prostate Cancer: A Pooled Analysis of Randomized Studies. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 203-209.	0.9	6
200	Impact of liver transplantation on the risk of second malignant tumors among hepatocellular carcinoma patients. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 865-869.	1.4	6
201	Revisiting the Prognostic Heterogeneity of AJCC Stage IV Carcinomas of the Upper Urinary Tract. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e859-e865.	0.9	6
202	Validation of the eighth clinical American Joint Committee on Cancer stage grouping for esophageal cancer. <i>Future Oncology</i> , 2018, 14, 65-75.	1.1	6
203	External validation of the 8th American Joint Committee on Cancer staging system for gall bladder carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 1084-1090.	0.6	6
204	Generalizability of clinical trials of advanced melanoma in the real-world, population-based setting. <i>Medical Oncology</i> , 2018, 35, 110.	1.2	6
205	Population-based validation of the National Cancer Comprehensive Network recommendations for breast cancer staging. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 231-238.	1.1	6
206	Impact of histological subtype on outcomes of renal cell carcinoma patients. <i>Journal of Drug Assessment</i> , 2018, 7, 14-20.	1.1	6
207	Bladder cancer mortality after a diagnosis of nonmuscle-invasive bladder carcinoma. <i>Future Oncology</i> , 2019, 15, 2267-2275.	1.1	6
208	Impact of Diabetes on the Outcomes of Patients With Castration-resistant Prostate Cancer Treated With Docetaxel: A Pooled Analysis of Three Phase III Studies. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e104-e112.	0.9	6
209	Revisiting the AJCC staging system of adrenocortical carcinoma. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 89-94.	1.8	6
210	Hepatocellular carcinoma (HCC); aetiological considerations. <i>Advances in Modern Oncology Research</i> , 2015, 1, 18.	0.1	6
211	Immune Checkpoints Aberrations and Malignant Mesothelioma: Assessment of Prognostic Value and Evaluation of Therapeutic Potentials. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2017, 17, 1228-1233.	0.9	6
212	Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 1123.	0.9	5
213	Risk of hematological toxicities in patients with solid tumors treated with ramucirumab: a meta-analysis. <i>Future Oncology</i> , 2015, 11, 2949-2961.	1.1	5
214	Targeting FGF receptors in colorectal cancer: from bench side to bed side. <i>Future Oncology</i> , 2015, 11, 1373-1379.	1.1	5
215	Risk of Distinctive Hair Changes Associated With Pazopanib in Patients With Renal Cell Carcinoma (RCC) Versus Patients Without RCC: A Comparative Systematic Review and Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e325-e335.	0.9	5
216	Impact of the staging method on the prognostic utility of the 8th AJCC staging system for non-small-cell lung cancer. <i>Future Oncology</i> , 2017, 13, 2277-2284.	1.1	5

#	ARTICLE	IF	CITATIONS
217	Outcomes of treatment with sorafenib in Egyptian patients with hepatocellular carcinoma: a retrospective cohort study. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 99-107.	1.4	5
218	Predictors of skeletal-related events among cancer patients with bone metastases treated with zoledronic acid: a secondary analysis of a randomized study. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 757-761.	1.0	5
219	Sex-based differences in outcomes of patients with HPV-positive versus HPV-negative oropharyngeal carcinoma: a population-based study. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 813-818.	1.1	5
220	Assessment of the AJCC staging system of pheochromocytomas/paragangliomas. <i>Endocrine</i> , 2022, 75, 239-243.	1.1	5
221	Characterization of a Novel Entity of G3 (High-grade Well-differentiated) Colorectal Neuroendocrine Tumors (NET) in the SEER Database. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 43-43.	0.6	5
222	Impact of baseline body mass index on the outcomes of patients with neuroendocrine neoplasms. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 1683-1688.	1.8	5
223	Combination of transarterial chemoembolisation (TACE) plus antivirals for the management of hepatitis B-related hepatocellular carcinoma: A systematic review of the literature. <i>Arab Journal of Gastroenterology</i> , 2015, 16, 40-45.	0.4	4
224	Targeting platelet-derived growth factor (PDGF) signaling in gastrointestinal cancers: preclinical and clinical considerations. <i>Tumor Biology</i> , 2015, 36, 21-31.	0.8	4
225	Risk of selected gastrointestinal and hepatic toxicities in cancer patients treated with nintedanib: a meta-analysis. <i>Future Oncology</i> , 2016, 12, 2163-2172.	1.1	4
226	Combination or single-agent ipilimumab as immunotherapy of advanced melanoma: a critical review. <i>Melanoma Management</i> , 2016, 3, 231-243.	0.1	4
227	Targeting <i>BRAF</i> aberrations in advanced colorectal carcinoma: from bench to bedside. <i>Future Oncology</i> , 2016, 12, 25-30.	1.1	4
228	S-1-based regimens for locally advanced/metastatic non-small-cell lung cancer: a meta-analysis. <i>Future Oncology</i> , 2016, 12, 701-713.	1.1	4
229	Incorporating age into International Germ Cell Consensus Classification (IGCCC): a time to move forward?. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 101-105.	1.1	4
230	Impact of Regional Nodal Irradiation on the Outcomes of N1 Breast Cancer Patients Referred for Adjuvant Treatment: A Patient-Level Pooled Analysis of 2 Clinical Trials. <i>Clinical Breast Cancer</i> , 2018, 18, 504-510.	1.1	4
231	The timing of chemotherapy in the management plan for medically operable early-stage malignant pleural mesothelioma. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 579-584.	1.0	4
232	Dietary Supplements Use among Adults with Cancer in the United States: A Population-Based Study. <i>Nutrition and Cancer</i> , 2021, 73, 1856-1863.	0.9	4
233	A 10-year review of survival among patients with metastatic gastrointestinal cancers: a population-based study. <i>International Journal of Colorectal Disease</i> , 2020, 35, 911-920.	1.0	4
234	Outcomes of small-cell versus large-cell gastroenteropancreatic neuroendocrine carcinomas: A population-based study. <i>Journal of Neuroendocrinology</i> , 2021, 33, e12971.	1.2	4

#	ARTICLE	IF	CITATIONS
235	Hospitalizations among early-stage colon cancer patients receiving adjuvant chemotherapy: a real-world study. <i>International Journal of Colorectal Disease</i> , 2021, 36, 1905-1913.	1.0	4
236	Gender, socioeconomic status and emergency department visits among cancer survivors in the USA: a population-based study. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 969-977.	0.6	4
237	Is smoking causally-associated with hepatitis B virus-related hepatocellular carcinoma?. <i>Annals of Translational Medicine</i> , 2019, 7, S44-S44.	0.7	4
238	Asian Americans have better outcomes of non-metastatic gastric cancer compared to other United States racial groups: A secondary analysis from a randomized study. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 1151-1160.	0.8	4
239	Sex-based differences in the outcomes of patients with lung carcinoids. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 523-531.	0.6	4
240	Risk of fatigue in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative meta-analysis. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 477-486.	1.1	3
241	M-bioscore: proposing a new statistical model for prognostic factors in metastatic breast cancer patients. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 845-854.	0.6	3
242	Impact of primary tumor side on the outcomes of patients with non-metastatic colon cancer; a patient-level pooled analysis of two clinical trials. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 843-848.	1.4	3
243	Population-based assessment of the performance of sigmoidoscopy in the detection of colorectal cancer: implications for future screening recommendations. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 354-356.	0.6	3
244	Impact of current versus former smoking status on the outcomes of non-metastatic non-small cell lung cancer treated with upfront surgery; findings from the National Lung Screening Trial. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 585-591.	1.0	3
245	Comparison of outcomes of radiotherapy-treated localized prostate cancer patients within a clinical trial setting versus real-life setting. <i>Future Oncology</i> , 2019, 15, 1269-1277.	1.1	3
246	Population-based validation of the National Cancer Comprehensive Network recommendations for baseline imaging workup of cutaneous melanoma. <i>Melanoma Research</i> , 2019, 29, 53-58.	0.6	3
247	A Real-World, Population-Based Study for the Incidence and Outcomes of Neuroendocrine Neoplasms of Unknown Primary. <i>Neuroendocrinology</i> , 2021, 111, 876-882.	1.2	3
248	Burden of depression among Canadian adults with cancer; results from a national survey. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 667-672.	0.7	3
249	Death from Alzheimer's disease among cancer survivors: a population-based study. <i>Current Medical Research and Opinion</i> , 2020, 36, 835-841.	0.9	3
250	Outcomes of non-metastatic poorly differentiated gastroenteropancreatic neuroendocrine neoplasms treated with surgery: a real-world population-based study. <i>International Journal of Colorectal Disease</i> , 2021, 36, 941-947.	1.0	3
251	Immunotherapy in Neuroendocrine Neoplasms: Where Are We Now?. <i>Current Treatment Options in Oncology</i> , 2021, 22, 19.	1.3	3
252	Real-world patterns of adjuvant chemotherapy treatment for patients with resected pancreatic adenocarcinoma. <i>Medical Oncology</i> , 2021, 38, 18.	1.2	3

#	ARTICLE	IF	CITATIONS
253	Outcomes of Ramucirumab Plus Paclitaxel Among Patients With Previously Treated Metastatic Gastric/Lower Esophageal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 158-161.	0.6	3
254	The impact of gender and HPV status on anal squamous cell carcinoma survival. <i>International Journal of Colorectal Disease</i> , 2021, 36, 2093-2109.	1.0	3
255	Patterns of cost-related medication underuse among Canadian adults with cancer: a cross-sectional study using survey data. <i>CMAJ Open</i> , 2021, 9, E474-E481.	1.1	3
256	Risk of arterial and venous thromboembolic events among patients with colorectal carcinoma: a real-world, population-based study. <i>Future Oncology</i> , 2021, 17, 3977-3986.	1.1	3
257	Patterns of colorectal cancer diagnosis among younger adults in a real-world, population-based cohort. <i>Future Oncology</i> , 2022, 18, 00-00.	1.1	3
258	Sphenoidal esthesioneuroblastoma treated with sequential chemo radiotherapy: A case report and review of the literature. <i>Journal of Cancer Research and Therapeutics</i> , 2014, 10, 1101.	0.3	2
259	Rolapitant: a pooled analysis of its efficacy and safety in the prophylaxis of chemotherapy-induced nausea and vomiting. <i>Future Oncology</i> , 2016, 12, 871-879.	1.1	2
260	Clinical significance of miRNA-autophagy transcript expression in patients with hepatocellular carcinoma. <i>Biomarkers in Medicine</i> , 2017, 11, 641-656.	0.6	2
261	Assessment of the external validity of the American Joint Committee on Cancer 8th staging system for anal carcinoma. <i>Current Medical Research and Opinion</i> , 2018, 34, 923-929.	0.9	2
262	Outcomes of patients in the national cancer database treated non-surgically for localized rectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 589-600.	0.6	2
263	Incidence and predictors of 1-year mortality among 9236 breast cancer patients referred for adjuvant chemotherapy. <i>Future Oncology</i> , 2018, 14, 2335-2341.	1.1	2
264	Impact of Time to Start Systemic Therapy on the Outcomes of Patients with Metastatic Colorectal Cancer Treated with First Line FOLFOX Chemotherapy; a Patient-Level Pooled Analysis of Two Clinical Trials. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 1069-1074.	1.4	2
265	Patterns of on-treatment cardiac adverse events within three clinical trials of adjuvant anthracycline-based chemotherapy. <i>Breast Cancer</i> , 2018, 25, 723-728.	1.3	2
266	Is routine baseline brain imaging needed for all newly diagnosed non-small-cell lung cancer patients?. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 569-575.	0.6	2
267	Impact of Timeliness of Surgical Treatment on the Outcomes of Patients with Non-metastatic Non-small Cell Lung Cancer: Findings From the PLCO Trial. <i>World Journal of Surgery</i> , 2019, 43, 2927-2933.	0.8	2
268	Assessment of the external validity of the AJCC 8th staging system for small intestinal adenocarcinoma: a time to reconsider the role of tumor location?. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 421-428.	0.6	2
269	Outcomes of Prostatectomy versus Radiation Therapy in the Management of Clinically Localized Prostate Cancer Patients Within the PLCO Trial. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e329-e338.	0.9	2
270	Population-based validation of the National Comprehensive Cancer Network's recommendations for baseline imaging for bladder cancer: a case for routine baseline bone scan?. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 157-163.	0.6	2



#	ARTICLE	IF	CITATIONS
271	Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. The Cochrane Library, 2021, 2021, CD011313.	1.5	2
272	New paradigms in the treatment of low-risk thyroid cancer. Expert Review of Endocrinology and Metabolism, 2020, 15, 251-260.	1.2	2
273	Subtype-specific risk factors for postmenopausal breast cancer: findings from the PLCO trial. Clinical and Translational Oncology, 2020, 22, 1885-1891.	1.2	2
274	Vitamin and herbal supplementsâ€™ use among patients with advanced gastrointestinal cancers included in eight clinical trials. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2089-2097.	1.2	2
275	Patient-Reported Cognitive and Functional Impairments Among Older Canadians With Cancer: a Population-Based Study. Journal of Pain and Symptom Management, 2021, 61, 279-286.	0.6	2
276	What is the real value of metronomic chemotherapy in the treatment of gastrointestinal cancer?. Expert Opinion on Pharmacotherapy, 2021, 22, 2297-2302.	0.9	2
277	Impact of postoperative radiotherapy on the outcomes of resected adrenocortical carcinomaâ€”a real-world, population-based study. Strahlentherapie Und Onkologie, 2022, 198, 73-79.	1.0	2
278	Racial Background and Health Behaviors Among Adults With Cancer in Canada: Results of a National Survey. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, , 1-9.	2.3	2
279	Association between PD-L1 inhibitor, tumor site and adverse events of potential immune etiology within the USâ€™FDA adverse event reporting system. Immunotherapy, 2021, 13, 1407-1417.	1.0	2
280	Factors associated with fatal coronavirus disease 2019 infections among cancer patients in the USâ€™FDA Adverse Event Reporting System database. Future Oncology, 2021, 17, 5045-5051.	1.1	2
281	Cyclin-dependent Kinases 4/6 Inhibitors in Neuroendocrine Neoplasms: from Bench to Bedside. Current Oncology Reports, 2022, 24, 715-722.	1.8	2
282	Patterns of emergency department visits preceding colorectal cancer diagnosis: a population-based study. Journal of Comparative Effectiveness Research, 2022, 11, 311-318.	0.6	2
283	Pregnancy and perinatal outcomes following exposure to antineoplastic agents around pregnancy within the US FDA Adverse Event Reporting System. Future Oncology, 2022, 18, 2635-2642.	1.1	2
284	Radical multimodality therapy for malignant pleural mesothelioma. The Cochrane Library, 2017, , .	1.5	1
285	Dissecting the heterogeneity of stage III non-small-cell lung cancer through incorporation of grade and histology. Future Oncology, 2017, 13, 2811-2821.	1.1	1
286	External validation of the prostatescore model in patients with metastatic hormoneâ€”sensitive prostate cancer recruited to the CHARTED study. BJU International, 2018, 122, 394-400.	1.3	1
287	Revisiting the prognostic relevance of muscle mass among non-metastatic colorectal cancer. Translational Gastroenterology and Hepatology, 2018, 3, 55-55.	1.5	1
288	Reply to the letter to the editor â€”Comment to â€”Impact of postmastectomy radiotherapy on the outcomes of breast cancer patients with T1-2 N1 disease; an individual patient data analysis of three clinical trialsâ€™. Strahlentherapie Und Onkologie, 2019, 195, 308-309.	1.0	1

#	ARTICLE	IF	CITATIONS
289	Population-based assessment of the National Comprehensive Cancer Network recommendations for baseline imaging of rectal cancer. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 1167-1172.	0.6	1
290	Limited surgery following neoadjuvant treatment among patients with localized rectal cancer; a population-based study. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 1221-1225.	1.4	1
291	Prevalence and healthcare utilization of acute respiratory infections among cancer survivors in the United States: a population-based study. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 697-704.	1.0	1
292	Comparison of oral versus intravenous etoposide in the management of small-cell lung cancer; A real-world, population-based study. <i>Clinical Respiratory Journal</i> , 2021, 15, 36-41.	0.6	1
293	Patterns of cigarette smoking and alcohol drinking among Canadian adults with cancer in a contemporary national cohort. <i>Journal of Cancer Survivorship</i> , 2023, 17, 130-138.	1.5	1
294	Disparities in modifiable cancer risk factors among Canadian provinces, territories, and health regions. <i>Current Medical Research and Opinion</i> , 2021, 37, 1-17.	0.9	1
295	A foreword from the editor. <i>Advances in Modern Oncology Research</i> , 2015, 1, 1.	0.1	1
296	Cisplatin-Based versus Carboplatin-Based Chemotherapy for Extrapulmonary Neuroendocrine Carcinomas: A Real-World Study. <i>Neuroendocrinology</i> , 2022, 112, 777-783.	1.2	1
297	Prognostic and predictive value of microsatellite instability status among patients with colorectal cancer. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 1197-1214.	0.6	1
298	Impact of cytoreductive surgery on outcomes of metastatic appendiceal carcinoma: a real-world, population-based study. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 431-439.	0.6	1
299	The role of surgery in small differentiated thyroid cancer. <i>Endocrine</i> , 2022, 77, 469-479.	1.1	1
300	A Real-World Study of the Incidence and Outcomes of Early-Onset Well-differentiated Neuroendocrine Neoplasms. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2022, 45, 338-343.	0.6	1
301	New hope on the horizon for patients with metastatic colorectal cancer. <i>Colorectal Cancer</i> , 2015, 4, 229-239.	0.8	0
302	Targeting metabolic peculiarities: a potentially novel therapeutic approach for KRAS-mutant lung cancer?. <i>Journal of Thoracic Disease</i> , 2016, 8, E794-E795.	0.6	0
303	S-1-based regimens and the risk of leucopenic complications; a Meta-analysis with comparison to other fluoropyrimidines and non fluoropyrimidines. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 437-448.	1.0	0
304	Impact of prior malignancies on the outcome of colorectal cancer: Revisiting clinical trial eligibility criteria. <i>Porto Biomedical Journal</i> , 2017, 2, 212.	0.4	0
305	Dissecting the heterogeneity of localized prostate cancer risk groups through integration of percent of positive cores. <i>Future Oncology</i> , 2018, 14, 1469-1476.	1.1	0
306	Population-based assessment of the national comprehensive cancer network recommendations for baseline imaging of hepatocellular carcinoma. <i>Medical Oncology</i> , 2019, 36, 26.	1.2	0

#	ARTICLE	IF	CITATIONS
307	Outcomes of clinically localized prostate cancer patients managed with initial monitoring approach versus upfront local treatment: a North American population-based study. <i>Clinical and Translational Oncology</i> , 2019, 21, 1673-1679.	1.2	0
308	Immune checkpoint inhibitors for unresectable hepatocellular carcinoma. <i>The Cochrane Library</i> , 0, , .	1.5	0
309	Evaluating Family History Links between Breast Cancer and Prostate Cancer Among PLCO Trial Participants. <i>Clinical Breast Cancer</i> , 2020, 20, 300-306.	1.1	0
310	Real-world Patterns of Adjuvant Chemotherapy Following Neoadjuvant Chemoradiation for Patients With Resected Rectal Adenocarcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 383-387.	0.6	0
311	Patterns and association of vaccination among adults with a history of cancer in the USA: a population-based study. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 899-907.	0.6	0
312	Outcomes of patients with nonmetastatic gastric adenocarcinoma according to perioperative treatment strategy: a real-world, population-based study. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 1143-1151.	0.6	0
313	Experiences of cancer patients with outpatient care in the USA: a population-based study. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 959-967.	0.6	0
314	Socioeconomic disparities in the prevalence of comorbid chronic conditions among Canadian adults with cancer. <i>Acta Oncologica</i> , 2022, 61, 294-301.	0.8	0
315	Outcomes of liver transplantation as an oncologic surgery for different primary liver cancers: A real-world, population-based study. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2021, , .	0.6	0
316	A real-world, population-based study for the outcomes of patients with metastatic colorectal cancer to the liver with distant lymph node metastases treated with metastasectomy. <i>Journal of Comparative Effectiveness Research</i> , 2022, , .	0.6	0
317	Changes in Survival Outcomes of Patients With Neuroendocrine Neoplasms Over the Past 15 Years. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2022, Publish Ahead of Print, .	0.6	0
318	Impact of intensive multimodal treatment on the outcomes of patients with anaplastic thyroid cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6082-6082.	0.8	0
319	Impact of perioperative chemotherapy on survival outcomes among patients with metastatic colorectal cancer to the liver. <i>Journal of Comparative Effectiveness Research</i> , 0, , .	0.6	0